Jaderson Sócrates

Consultant GLG

Rio de Janeiro, BR

How does this work?

Consolidated experience in Drug R&D and Health Technology Development with a demonstrated professional expertise in the pharmaceuticals industry. Academic experience through a 35 years career as an Adjunct Professor at the School of Medicine of the Federal University of Rio de Janeiro -Strong healthcare services professional skilled in Epidemiology, Oncology, Good Clinical Practice (GCP), Pharmacovigilance, Pharmacology and Toxicology, Clinical Trials, Internal Medicine and Drug R&D.

Ask me about
Drug R&D
Research and Development
Health Technology Development
pharmaceuticals industry
Good Clinical Practice (GCP)
Internal Medicine
Pharmacology and Toxicology
Clinical Trials
Work experience

Sep 2016 - Present

Freyr Solutions


Feb 2016 - Present

Mintebi ApS Sankt Annae Plads 11 1250­Copenhagen, Denmark www.mintebi.com


Nov 2015 - Present

Aliança Pesquisa Clínica Brasil

Director of Institutional Relations

Non-profit civic organization encompassing patients associations, researchers, medical and scientific societies, academia, pharmaceutical, biotech and healthcare companies.

Sep 2015 - Present

GLG (Gerson Lehrman Group)



Sep 2015 - Present

SinoVeda Canada Inc.


Brazil and Latin America Business Development for Pharmaceuticals, Consumer Health Products and Functional Foods / Pharmaceutical Platform Technology (PPT) for Herbal Medicines' Drug Discovery and Development


Feb 2015 - Present

Independent Consultant

Drug Discovery and Development & Health Technology

After 18 years working at Sanofi, It was decided to retire from the company and act as an independent consultant. Those years at Sanofi were an enlightment in my professional and personal career and I am very thankfull to all those peers and friends who made an outstanding contribution to this period of my life.

Sep 2018 - Jun 2020

Cient Periodique, Toronto, Canada.

Member of the Editorial Board of CPQ Medicine, Canada.


Mar 2016 - Dec 2017

Implicit Bioscience


Business Development for Brazil / Clinical Research.


Oct 2015 - Oct 2017

JSS Medical Research


Clinical Research /Business Development in Brazil and Latin America


Aug 2015 - Jul 2016


Medical and Scientific Consultant

Diabetes and Atopic Diseases / Clinical Research


Jan 2011 - Jan 2015


Medical and Scientific Alliances Director

Actual position: Medical and Scientific Alliances Director, reporting to the General Manager of Sanofi Group Brazil, since January 2011. Member of the Sanofi R&D scouting and external innovation team. He is responsible for R&D scouting activities, medical and scientific alliances and partnerships with governmental, academic (public and private) institutions. Scout, initiate and coordinate innovative research projects / technologies, diligent technical analysis of clinical needs, from E2C (Early-to-Candidate), to clinical development stages. Establishing Interfaces between the scientific community, main academic centers, government authorities and biotechnology companies (innovation in healthcare science and technology). Member of the Board of Directors, Sanofi Group Brazil. Current Clinical Study Unit (CSU), responsible for the design, plan and execution of clinical trials activities in Brazil, has a matrix reporting line to me(dotted). It is running over 100 trials (including PK/phase I) in several therapeutic areas, e.g. oncology, cardiovascular, immunology, degenerative diseases, etc. Studies are being conducted in more than 300 centers, including (multicentre, multinational trials, local trials, epidemiologic studies (Registries), Investigators’ Sponsored Trials, bioavailability and bioequivalence studies for generics and similar products (see S-A clinical trials in Brazil at: www.clinicaltrials.gov ).

Mar 1980 - Jul 2013

Universidade Federal do Rio de Janeiro

Adjunct Professor - Department of Internal Medicine

From 2005 to 2011, I was licenced from the University. Back to my academic activities, upon request of local Health Authorities the university agreed to share my professional expertise serving as a scientific advisor of the Secretary of Health (City of Rio de Janeiro) in chemical safety (Poison Control Center of Rio de Janeiro). - After 30 years of university career, teaching at the Federal University of Rio de Janeiro, I decided to request my retirement (voluntary retirement, Law 8112/90, published in the Oficial Gazere -D.O.U, August 2nd 2013), to better focus my professional activities in the medical and scientific areas of interest.


1998 - 2010


Medical Director

Former positions / appointments in the same company: Medical Director, October 2004 to December 2010, reporting to the General Manager and functionally to the Intercontinental Direction (Headquarters). Clinical trials Unit, Pharmacovigilance, Affiliate Quality Officer and Medical Marketing were divisions of this medical direction organizational structure. . Medical Director (from October 1999 to October 2004) and Clinical Research Unit Head (Sanofi-Synthélabo Ltda. Brazil, since September 2001), reporting to the General Manager and to the Worldwide Clinical Development of Sanofi-Synthelabo Recherche (France), being responsible for the medical and regulatory affairs department and the management of multicenter/ multinational studies (actually more than one hundred centers are involved in the R&D Sanofi-Synthelabo trials in Brazil). The direct reports to the medical direction include one Regulatory Affairs Manager, one Clinical Research Operations Manager and one Clinical Research Manager, one Local safety Officer and Medical Information Manager as well as four Medical Managers giving support to the marketing activities. . Clinical Research Manager and Local Safety Officer – Sanofi-Winthrop Farmacêutica Ltda.- From January 1998 to September 1999, reporting to the Medical Director, being responsible for the preparation and conduction of clinical trials from phases II to IV. Responsible for the Pharmacovigilance activities (Local Safety Officer). The main research areas were cardiology, thrombosis, internal medicine, oncology, rheumatology, central nervous system and psychiatry. The research also involved PK studies (bioavailability and bio- equivalence). Some studies were undertaken to launch products in Brazil and Latin American countries and the accumulated experience also encompassed multicenter/multinational phases II/III trials.

Board Certified

Talk to Jaderson

@ Copyright 2020 OfficeHours Technologies Co.